Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma

Por Stringer, Erica M, Fleming, Gini F
Publicado no Oncol Hematol Rev (2013)

Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings

Por Bestvina, Christine M., Fleming, Gini F.
Publicado no Oncologist (2016)

Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study

Por Mould, Diane R, Fleming, Gini F, Darcy, Kathleen M, Spriggs, David
Publicado em 2006

Chemotherapy-Induced Peripheral Neuropathy: Current Status and Progress

Por Brewer, Jamie R, Morrison, Gladys, Dolan, M. Eileen, Fleming, Gini F
Publicado no Gynecol Oncol (2015)

The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years

Por Gibson, Steven J., Fleming, Gini F., Temkin, Sarah M., Chase, Dana M.
Publicado no Front Oncol (2016)

Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report

Por VanderWeele, David J., Paner, Gladell P., Fleming, Gini F., Szmulewitz, Russell Z.
Publicado no Front Oncol (2015)

Nanomedicine for Combination Therapy of Cancer

Por He, Chunbai, Chan, Christina, Weichselbaum, Ralph R., Fleming, Gini F., Yamada, S. Diane, Lin, Wenbin
Publicado no EBioMedicine (2015)

Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion

Por Fleming, Gini F, Schumm, Philip, Friberg, Greg, Ratain, Mark J, Njiaju, Uchenna O, Schilsky, Richard L
Publicado no BMC Cancer (2015)

Bilateral Optic Disc Swelling Following Anastrozole Therapy

Por Coppes, Oscar Jim Michael, Lukas, Rimas V., Fleming, Gini F., Nichols, Jeffrey, Tenney, Meaghan, Bernard, Jacqueline
Publicado no Neuroophthalmology (2014)

Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment

Por Maranville, Joseph C, Nanda, Rita, Fleming, Gini F, Skor, Maxwell N, Di Rienzo, Anna, Conzen, Suzanne D
Publicado em 2014

Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing

Por Jang, Miran, Yew, Poh-Yin, Hasegawa, Kosei, Ikeda, Yuji, Fujiwara, Keiichi, Fleming, Gini F, Nakamura, Yusuke, Park, Jae-Hyun
Publicado no Oncoimmunology (2015)

Administration of Glucocorticoids to Ovarian Cancer Patients Is Associated with Expression of the Anti-apoptotic Genes SGK1 and MKP1/DUSP1 in Ovarian Tissues

Por Melhem, Amal, DianeYamada, S., Fleming, Gini F., Delgado, Bertha, Brickley, Deanna R., Wu, Wei, Kocherginsky, Masha, Conzen, Suzanne D.
Publicado no Clin Cancer Res (2009)

Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer

Por Bhatta, Sumita S, Hou, Ningqi, Moton, Zakiya N, Polite, Blase N, Fleming, Gini F, Olopade, Olufunmilayo I, Huo, Dezheng, Hong, Susan
Publicado em 2013

Glucocorticoid Receptor Activation Inhibits Chemotherapy-induced Cell Death in High-grade Serous Ovarian Carcinoma

Por Stringer-Reasor, Erica M., Baker, Gabrielle M., Skor, Maxwell N., Kocherginsky, Masha, Lengyel, Ernst, Fleming, Gini F., Conzen, Suzanne D.
Publicado no Gynecol Oncol (2015)

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

Por Mani, Aruna, Roda, Julie, Young, Donn, Caligiuri, Michael A., Fleming, Gini F., Kaufman, Peter, Brufsky, Adam, Ottman, Susan, Carson, William E., Shapiro, Charles L.
Publicado em 2008

Efficacy and Safety of Bevacizumab Plus Erlotinib for Patients with Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer: A Trial of the Chicago, PMH, and California Ph...

Por Nimeiri, Halla S., Oza, Amit M., Morgan, Robert J., Friberg, Gregory, Kasza, Kristen, Faoro, Leonardo, Salgia, Ravi, Stadler, Walter M., Vokes, Everett E., Fleming, Gini F.
Publicado em 2008

A Phase II Study of Sorafenib in Advanced Uterine Carcinoma / Carcinosarcoma: A Trial of the Chicago, PMH, and California Phase II Consortia

Por Nimeiri, Halla S., Oza, Amit M., Morgan, Robert J., Huo, Dezheng, Elit, Laurie, Knost, James A., Wade, James L., Agamah, Edem, Vokes, Everett E., Fleming, Gini F.
Publicado em 2010

Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy

Por Ezewuiro, Obiageli, Grushko, Tatyana A., Kocherginsky, Masha, Habis, Mohammed, Hurteau, Jean A., Mills, Kathryn A., Hunn, Jessica, Olopade, Olufunmilayo I., Fleming, Gini F., Romero, Iris L.
Publicado no PLoS One (2016)

CHEMOTHERAPY INTENSITY AND TOXICITY AMONG BLACK AND WHITE WOMEN WITH ADVANCED AND RECURRENT ENDOMETRIAL CANCER: A GYNECOLOGIC ONCOLOGY GROUP STUDY

Por Farley, John H., Tian, Chunqiao, Rose, G. Scott, Brown, Carol L., Birrer, Michael, Risinger, John I, Thigpen, J. Tate, Fleming, Gini F., Gallion, Holly H., Maxwell, G. Larry
Publicado em 2010

A Phase 1 trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cance...

Por Liu, Joyce F., Tolaney, Sara M., Birrer, Michael, Fleming, Gini F., Buss, Mary K., Dahlberg, Suzanne E., Lee, Hang, Whalen, Christin, Tyburski, Karin, Winer, Eric, Ivy, Percy, Matulonis, Ursula A.
Publicado em 2013